Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) have earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $54.71.

COAG has been the subject of a number of recent analyst reports. Rodman & Renshaw initiated coverage on Hemab Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $56.00 price target for the company. Jefferies Financial Group boosted their price target on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Weiss Ratings cut shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. JPMorgan Chase & Co. started coverage on shares of Hemab Therapeutics in a report on Thursday, October 15th. They set an “overweight” rating and a $70.00 price objective on the stock. Finally, Wedbush lifted their price objective on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th.

Hemab Therapeutics Stock Performance

Shares of NASDAQ COAG opened at $41.45 on Monday. The stock has a market capitalization of $1.94 billion and a P/E ratio of -1.67. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $55.42. The business’s 50-day moving average price is $37.90.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, analysts expect that Hemab Therapeutics will post -3.10 EPS for the current fiscal year.

Institutional Trading of Hemab Therapeutics

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its position in Hemab Therapeutics by 77.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,400 shares of the company’s stock valued at $209,000 after buying an additional 2,800 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Hemab Therapeutics during the 2nd quarter valued at $230,000. Profund Advisors LLC purchased a new stake in Hemab Therapeutics during the 3rd quarter valued at about $246,000. The Manufacturers Life Insurance Company bought a new stake in Hemab Therapeutics in the 2nd quarter worth approximately $688,000. Finally, Opaleye Management Inc. bought a new position in shares of Hemab Therapeutics in the second quarter worth approximately $1,750,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.